Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 4:29 pm Sale | 13G | AN2 Therapeutics Inc. ANTX | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -1,563,963 (Position Closed) | View |
| 2024-11-14 4:16 pm Sale | 13G | AN2 Therapeutics Inc. ANTX | CITADEL ADVISORS LLC | 22 0.000% | -1,556,820 (-100.00%) | View |
| 2024-11-13 4:25 pm Sale | 13G | AN2 Therapeutics Inc. ANTX | TCG Crossover GP I LLC | 1,555,118 5.200% | -1,123,091 (-41.93%) | View |
| 2024-08-28 4:02 pm Sale | 13G | AN2 Therapeutics Inc. ANTX | Octagon Capital Advisors LP | 0 0.000% | -3,009,927 (Position Closed) | View |
| 2024-08-14 9:00 pm Purchase | 13G | AN2 Therapeutics Inc. ANTX | BML Investment Partners L.P. | 5,749,432 19.300% | 1,500,000 (+35.30%) | View |
| 2024-08-13 5:40 pm Sale | 13G | AN2 Therapeutics Inc. ANTX | RA CAPITAL MANAGEMENT L.P. | 1,999,997 6.700% | -3,551,298 (-63.97%) | View |
| 2024-08-12 4:48 pm Purchase | 13G | AN2 Therapeutics Inc. ANTX | BML Investment Partners L.P. | 4,249,432 14.200% | 4,249,432 (New Position) | View |
| 2024-07-03 08:02 am Purchase | 13G | AN2 Therapeutics Inc. ANTX | Octagon Capital Advisors LP | 3,009,927 10.100% | 3,009,927 (New Position) | View |
| 2024-04-10 4:44 pm Purchase | 13G | AN2 Therapeutics Inc. ANTX | Frazier Life Sciences Public Fund L.P. | 1,488,889 5.000% | 1,488,889 (New Position) | View |
| 2024-02-14 5:01 pm Purchase | 13G | AN2 Therapeutics Inc. ANTX | RA CAPITAL MANAGEMENT L.P. | 5,551,295 18.700% | 1,777,778 (+47.11%) | View |
| 2024-02-14 4:57 pm Purchase | 13G | AN2 Therapeutics Inc. ANTX | CITADEL ADVISORS LLC | 1,556,842 5.200% | 219,849 (+16.44%) | View |
| 2024-02-14 2:29 pm Purchase | 13G | AN2 Therapeutics Inc. ANTX | PFIZER INC PFE | 1,362,499 4.580% | 1,362,499 (New Position) | View |
| 2024-02-13 5:11 pm Purchase | 13G | AN2 Therapeutics Inc. ANTX | Easom Eric | 1,572,170 5.200% | 1,572,170 (New Position) | View |
| 2024-02-12 2:05 pm Purchase | 13G | AN2 Therapeutics Inc. ANTX | JANUS HENDERSON GROUP PLC JHG | 1,279,975 4.300% | 279,899 (+27.99%) | View |
| 2024-02-09 4:29 pm Purchase | 13G | AN2 Therapeutics Inc. ANTX | TCG Crossover GP I LLC | 2,678,209 9.000% | 1,388,889 (+107.72%) | View |
| 2024-02-09 07:06 am Sale | 13G | AN2 Therapeutics Inc. ANTX | Adjuvant Global Health Technology Fund L.P. | 2,473,500 8.300% | -123,880 (-4.77%) | View |
| 2023-07-25 4:19 pm Purchase | 13G | AN2 Therapeutics Inc. ANTX | TCG Crossover GP I LLC | 1,289,320 6.600% | 1,289,320 (New Position) | View |
| 2023-07-05 4:55 pm Purchase | 13G | AN2 Therapeutics Inc. ANTX | JANUS HENDERSON GROUP PLC JHG | 1,000,076 5.100% | 1,000,076 (New Position) | View |
| 2023-02-14 4:45 pm Purchase | 13G | AN2 Therapeutics Inc. ANTX | RA CAPITAL MANAGEMENT L.P. | 3,773,517 19.500% | 106,854 (+2.91%) | View |
| 2023-02-14 11:45 am Sale | 13G | AN2 Therapeutics Inc. ANTX | BIOTECHNOLOGY VALUE FUND L P | 1,563,963 8.100% | -52,702 (-3.26%) | View |